Health Economics›B-cell acute lymphoblastic leukemia›Upfront induction therapy

Upfront induction therapy

B-cell acute lymphoblastic leukemia · 29 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dasatinib and Prednisone Variant #02	BCR::ABL1	R 54 281	84d	—	—	—	—	—
Cyclophosphamide, Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Rituximab Variant #01	—	R 37 764	—	—	—	—	—	—
Daunorubicin, L-Asparaginase, Vincristine, Prednisone, Imatinib Variant #01	BCR::ABL1	R 22 719	28d	—	—	—	—	—
R-Hyper-CVAD/R-MA Variant #01	—	R 22 261	—	—	—	—	—	—
Cyclophosphamide, Daunorubicin, L-Asparaginase, Vincristine, Prednisone N/A - intrathecal component	—	R 21 728	28d	—	—	—	—	—
Daunorubicin, Vincristine, Prednisolone, Nilotinib Variant #01	BCR::ABL1	R 18 223	14d	—	—	—	—	—
Cyclophosphamide, Idarubicin, Vincristine, Prednisone Variant #01	—	R 17 706	28d	—	—	—	—	—
Hyper-CVAD/MA and Dasatinib Variant #01	BCR::ABL1	R 17 523	—	—	—	—	—	—
Hyper-CVAD/MA and Imatinib Variant #01	BCR::ABL1	R 16 354	—	—	—	—	—	—
Imatinib and Prednisone Variant #01	BCR::ABL1	R 15 104	50d	—	—	—	—	—
Imatinib, Vincristine, Dexamethasone Variant #01	BCR::ABL1	R 12 553	28d	—	—	—	—	—
Hyper-CVAD/MA Variant #01	—	R 10 888	—	—	—	—	—	—
Cyclophosphamide, Daunorubicin, Vincristine, Prednisolone Variant #01	—	R 10 457	28d	—	—	—	—	—
Cyclophosphamide, Daunorubicin, Vincristine, Prednisone Variant #01	—	R 10 428	28d	—	—	—	—	—
Idarubicin, L-Asparaginase, Vincristine, Prednisone Variant #01	—	R 10 133	35d	—	—	—	—	—
Cyclophosphamide, Doxorubicin, L-asparaginase, Vincristine, Prednisolone Variant #01	—	R 2 625	35d	—	—	—	—	—
Mini-Hyper-CVD/MA and Inotuzumab ozogamicin Variant #01 Partial	—	R 2 361	28d	—	—	—	—	—
Mercaptopurine and Methotrexate Variant #05	—	R 2 336	14d	—	—	—	—	—
Ponatinib, Vincristine, Dexamethasone Variant #01 Partial	BCR::ABL1	R 1 083	28d	—	—	—	—	—
Cyclophosphamide, Cytarabine, Mercaptopurine Variant #01	—	R 1 025	29d	—	—	—	—	—
L-Asparaginase, Vincristine, Prednisone Variant #01	—	R 908	28d	—	—	—	—	—
Hyper-CVAD/MA and Ponatinib N/A - secondary systemic drug Partial	BCR::ABL1	R 425	—	—	—	—	—	—
Prednisolone monotherapy Variant #03	—	R 109	84d	—	—	—	—	1
DOLP N/A - intrathecal component	—	R 71	42d	—	—	—	—	—
Daunorubicin, Pegaspargase, Vincristine, Dexamethasone N/A - intrathecal component	—	R 67	28d	—	—	—	—	—
Daunorubicin, Pegaspargase, Vincristine, Prednisone N/A - intrathecal component	—	R 66	28d	—	—	—	—	—
Prednisone monotherapy Variant #11	—	R 22	7d	~2.2 mo	~14.1 mo	~10	~R 215 PFS proxy · indirect	8
Blinatumomab monotherapy N/A - secondary systemic drug	—	R 18	28d	—	~7.7 mo	—	—	2
Ponatinib and Blinatumomab Variant #01 Partial	BCR::ABL1	—	42d	—	—	—	—	—

29 of 29 regimens shown